Emmes – a global Contract Research Organisation (CRO) dedicated to support the advancement of public health and biopharma innovation – has rapidly expanded its capabilities in India during the last two years. The company’s operations in India have seen surging growth with local revenue increasing by 400 per cent and global study revenue increasing by more than 50 per cent, a statement from the company has notified.
The CRO forecasts its Indian operations will grow further over the next year, with employee numbers quickly surpassing 200. Over 60 per cent growth has been achieved over the past year with continued high growth planned over the next three years, said the statement.
It also informed that the company’s expertise in vaccines and infectious diseases are its particular strengths. It has a strong pedigree in vaccines, and has completed several trials in India, Bangladesh and Africa – including for tuberculosis, shigellosis, enterotoxigenic Escherichia coli (ETEC), polio, human papillomavirus (HPV), yellow fever, Respiratory Syncytial Virus (RSV), influenza, COVID-19 and typhoid.
“Our teams have worked on a number of global clinical trials in close collaboration with the wider organisation, and, of course, on several COVID-19 trials. The team’s commitment to quality, customer satisfaction, innovation and the drive to make a public health impact is what sets us apart from other CROs in India working on international projects. However, what is perhaps less known is that we have also seen significant growth from innovators in India and have led numerous clinical trials here,” commented Archana Sarda, Managing Director, Emmes India, in the statement.
Exponential growth in the size of the local team and services offered has resulted in enhanced ability to support large phase-III and IV studies. The team in India is currently leading five phase-III trials for global clients. Looking ahead to 2023, with its lineage in comparable research and the access to patients locally, the Emmes team in India has identified indigenously developed vaccine trials as a strong growth area, as well as a broad spectrum of trials from international sponsors, concluded the statement.